and its prevalence is expected to rise together with extended life expectancy. 2 Eight to 12% of ischemic strokes result in death within 30 days, 3 while surviving patients are at an increased risk for a subsequent vascular event, the most common being a second stroke. 4, 5 The risk of recurrent stroke or transient ischemic attack (TIA) is between 5 and 15% per year, and is highest immediately following the primary episode. 6, 7 This accounts for approximately three-quarters of all secondary vascular events following stroke. 4 Secondary prevention strategies focus on reducing cardiovascular risk factors such as cigarette smoking, diabetes mellitus (DM), obesity, and high blood pressure and cholesterol levels. 8 In addition, pharmacological antiplatelet therapy is indicated in such patients, ASA being the the most widely used. Clinical trials have shown that treating stroke patients with ASA significantly reduces the risk of a recurrent episode compared with placebo. [9] [10] [11] The protective effect was found not to be dosedependent, leading to the use of lower doses with a more favorable side effect profile.
To explore other treatment possibilities, later studies compared the efficacy and safety of alternate antiplatelet drugs with ASA in secondary stroke
prevention. The Clopidogrel versus Aspirin in Patients at Risk of Ischaemic
Events (CAPRIE) trial examined the efficacy of clopidogrel compared with ASA in preventing recurrent vascular events among patients suffering from stroke, myocardial infarction (MI), or a history of peripheral arterial disease. 12 Although clopidogrel was found to be more effective among the general study population, this was not significant in the stroke subgroup, and clopidogrel was deemed to be as good as an ASA only in preventing stroke. In addition to antiplatelet treatment, stroke patients may also benefit from reductions in other significant risk factors, most notably in blood pressure. The use of drugs blocking the renin-angiotensin system has resulted in a significant reduction in vascular ischemic events. In the Heart Outcome Prevention Evaluation (HOPE) study, treatment with an angiotensin-converting enzyme (ACE) inhibitor resulted in a significant decline in ischemic events among patients with previous vascular disease or diabetes. 18 The results indicated that blocking the renin-angiotensin pathway may have achieved its beneficial effect through mechanisms other than blood pressure reduction. Recent studies have also suggested that angiotensin II receptor blockers (ARBs) may have a similar effect in reducing the risk of recurring vascular events. 19, 20 However, these drugs are currently not routinely used for treatment of the majority of patients after stroke. Thus, to date, the issues regarding optimal antiplatelet treatment, as well as the role of ARBs, remain unresolved.
Study Goals
The PRoFESS trial was set up to answer two main questions: 'Is combination therapy of ASA + ER-DP more effective than clopidogrel alone at secondary stroke prevention?' and 'What is the added benefit of an ARB (telmisartan)
to secondary stroke prevention?' 
Telmisartan (Micardis ® )
Telmisartan is an oral active non-peptide type I ARB. It has a profound antihypertensive effect by selectively blocking the binding of angiotensin II to the AT 1 receptor. Thus, telmisartan impedes the vasoconstrictor effects of angiotensin II, independent of its rate of synthesis. It has been proposed that ARBs may exhibit neuroprotective properties in addition to their antihypertensive effect. 23 They may also play a role in the prevention of DM and renal function deterioration. 24 Telmisartan is approved for hypertension treatment by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA).
PRoFESS Trial Design
The PRoFESS trial is the largest clinical study to date aimed at examining secondary stroke prevention therapy. It is an ongoing, randomized, parallelgroup, multinational, double-blind, double-dummy, active, and placebocontrolled study. The trial includes 20,333 patients with stroke, enrolled at 695 sites in 35 countries across the globe. Patients are randomized to one of four study arms according to a 2x2 factorial design (see Figure 1) . The four groups were set up to compare ASA + ER-DP given twice daily with clopidogrel given once daily, and telmisartan given once daily with placebo.
Patients are assigned to a study group following two simultaneous randomizations, with randomization to telmisartan stratified based on current treatment with ACE inhibitors. 22 The main inclusion criteria regard Expected Implications for Oral Antiplatelet Therapy in Secondary Stroke Prevention Therapy
disease, recent major surgery, severe hepatic or renal insufficiency, and uncontrolled hyper/hypotension.
The primary end-point for the study is time to recurrent stroke of any type.
The secondary end-points are a composite of vascular events (stroke, MI, or vascular death), a composite of vascular events with new or worsened congestive heart failure, and new onset of diabetes. Follow-up evaluation is performed at one week, one month, three months, and six months, then at six-month intervals for the duration of the trial.
Four sub-studies have also been approved for the PRoFESS trial:
• a cognitive sub-study for determining whether the study medication can reduce the rate of cognitive decline;
• a hemodynamic sub-study that will investigate the hemodynamic effects of the study drugs, including any effects on central compliance, central blood pressure, myocardial perfusion, and other 24-hour ambulatory blood pressure measures;
• a magnetic resonance imaging (MRI) sub-study that will evaluate whether patients with silent infarcts have a higher risk of recurrent stroke and whether patients with white-matter lesions at study entry are developing vascular dementia more quickly; and
• a biomarker and genetic analysis sub-study that will perform these analyses on blood samples collected at baseline and after two years.
Baseline Data
During the recruitment period from September 2003 to June 2006, a total of 20,333 stroke patients were enrolled into the PRoFESS trial. 22 The average patient age at enrollment was 66.1±8.6 years, with 36% of the patients being women. The study included patients from diverse ethnic and racial backgrounds from across the globe. Patients were categorized according to 
PRoFESS and Future Stroke Prevention
The PRoFESS trial is the largest clinical study to date dedicated to examining secondary stroke prevention regimens. Previous studies have already shown that alternative drugs are as effective as or even superior to ASA in secondary stroke prevention. Clopidogrel was found to be an effective alternative to ASA, and the combination of ASA + ER-DP showed an increased benefit compared with ASA monotherapy in secondary stroke prevention. However, it remains unclear which of these two alternative regimens is the most effective treatment. The working hypothesis of the antiplatelet arm of the trial is that the combination of ASA + ER-DP will be more effective than clopidogrel alone in secondary stroke prevention. PRoFESS is intended to be able to answer questions regarding these issues among a general patient population.
The size of the cohort, together with its diversity of populations, will also allow for specific identification of different subgroups that might benefit from one of the antiplatelet treatment regimens or the addition of ARBs.
The cohort of patients enrolled in the trial represents a high-risk population; one-third have diabetes, two-thirds have hypertension, and approximately one-third have a concomitant cardiovascular disease.
PRoFESS is targeted to address therapy options for patients with an increased risk of a secondary event. Furthermore, with more than twothirds of the patients recruited during the early phase after a stroke and with more than 8,000 patients randomized within 10 days, PRoFESS will also be able to provide, for the first time, important information regarding the efficacy of starting antiplatelet and ARB treatment early after stroke. It should be noted that during the trial not only the benefit of each treatment arm will be recorded, but also possible adverse effects, in particular those related to bleeding complications. A difference in the bleeding risk may very well be a decisive factor in the recommendation of a first-line choice of treatment.
The sub-studies of the trial will explore any effect on mental deterioration in stroke patients, as well as the possible impact on silent infarcts and white matter lesions. Biomarker analyses may identify any potential role these might have in predicting secondary stroke occurrence.
The results of the PRoFESS trial will contribute to determining the choice of first-line prevention regimes among the general patient population, as well as in specific subpopulations. This will help physicians to better manage stroke patients and prevent recurrent events. Trial results are expected to be presented at the European Stroke Conference in May 2008. ■
